Skip to main content

Table 1 Genes and polymorphisms showing significant summary odds ratio (OR) of the addiction susceptibility from random/fixed-effects meta-analyses using allelic contrasts

From: Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction

Gene
Name
Polymorphism* Model
(Major allele > Minor Allele)
Cases vs. Controls (independent samples) Fixed Effects OR (95% CI) Random Effects OR (95% CI) Heterogeneity p- Value I-
Square
Grade**
SLC4A7 rs3278 G > A 1410 vs. 906 (3) 2.34 (1.599-3.420) 2.28 (1.555-3.333) 0.51 0 B
DRD4 48-bp repeat Other > 7/8 repeats 2324 vs. 1932 (6) 1.44 (1.155-1.804) 1.48 (1.000-2.197) 0.06 52 C
DRD2/
ANKK1***
Taq1A A2 > A1 6312 vs. 7424 (20) 1.30 (1.192-1.410) 1.38 (1.096-1.733) < 0.0001 84 C
BDNF rs6265 G > A 2530 vs. 4126 (9) 1.31 (1.165-1.451) 1.38 (1.056-1.790) < 0.0001 80 C
CCK -45 C/T C > T 860 vs. 2002 (6) 1.34 (1.089-1.650) 1.34 (1.083-1.646) 0.62 0 B
FAAH rs324420 P > T 498 vs. 1570 (3) 1.38 (1.014-1.875) 1.32 (0.807-2.171) 0.24 28 B
OPRM1 rs1799971 A > G 2846 vs. 4072 (9) 1.24 (1.090-1.410) 1.31 (0.958-1.790) < 0.0001 80 C
COMT rs4680 Val > Met 862 vs. 1594 (3) 0.76 (0.634-0.923) 0.82 (0.644-1.051) 0.71 0 B
CNR1 (AAT)n 14 repeats > Other 2304 vs. 2144 (8) 0.76 (0.658-0.878) 0.75 (0.619-0.906) 0.17 32 B
HNMT rs35953316 Thr > Ile 1540 vs. 1306 (3) 0.76 (0.598-0.975) 0.72 (0.444-1.179) 0.04 70 C
OPRK1 rs702764 A > G 292 vs. 246 (3) 0.62 (0.431-0.901) 0.62 (0.412-0.944) 0.99 0 B
OPRM1 C691G C > G 796 vs. 786 (3) 0.52 (0.416-0.647) 0.61 (0.330-1.095) 0.0025 83 C
  1. *Variants were ranked based on the summary ORs. **Degree of 'epidemiological credibility' based on published protocols (A, strong; B, modest; C, weak; see Methods for more details). ***Researchers previously associated the polymorphism Taq 1A to the DRD2 gene. However, the polymorphism sits in an exon of the ANKK1 gene.
\